Full Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript
Key Points
- Vivoryon Therapeutics NV (WBO:VVYN) has built a robust data package for varoglutamstat in kidney disease, supporting its partnering efforts.
- The company has presented compelling kidney function data at key nephrology meetings, highlighting the beneficial effects of varoglutamstat.
- Vivoryon Therapeutics NV (WBO:VVYN) has extended its intellectual property protection in the US until at least 2044.
- The company successfully raised EUR5.1 million in October 2025, enhancing its financial flexibility.
- There is strong and growing interest from biopharma companies and investors, with multiple discussions and due diligence processes underway.
- Research and development expenses decreased significantly from EUR14.1 million in 2024 to EUR4.3 million in 2025, indicating a potential slowdown in R&D activities.
- The company reported a net loss of EUR8.9 million for the year 2025.
- Cash and cash equivalents decreased from EUR9.4 million at the end of 2024 to EUR5.6 million at the end of 2025.
- Further development of R&D activities is dependent on additional financing and strategic partnerships.
- The number of patients with end-stage kidney disease remains stable, indicating a persistent high unmet medical need despite existing therapies.
Good day, and thank you for standing by. Welcome to Vivoryon Therapeutics full-year 2025 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Julia Neugebauer. Please go ahead.
Thank you, Sandra. Good morning or good afternoon, everyone, and thank you for joining us today for Vivoryon's full year 2025 results call. Earlier today, we issued a press release reporting our full year 2025 financial results and business update, which can be found on Vivoryon's website at www.vivoryon.com. On the call with me today are Frank Weber, our Chief Executive Officer; Marcus Irsfeld, our Chief Financial Officer; as well as Michael Schaeffer, our Chief Business Officer.
Before we start, I would like to remind you that during this conference call, we will present and discuss certain
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
